PT1373503E - ''factores neurotróficos'' - Google Patents

''factores neurotróficos'' Download PDF

Info

Publication number
PT1373503E
PT1373503E PT02706759T PT02706759T PT1373503E PT 1373503 E PT1373503 E PT 1373503E PT 02706759 T PT02706759 T PT 02706759T PT 02706759 T PT02706759 T PT 02706759T PT 1373503 E PT1373503 E PT 1373503E
Authority
PT
Portugal
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
PT02706759T
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony Rossomando
Dinah Wen Yee Sah
Teit E Johansen
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Publication of PT1373503E publication Critical patent/PT1373503E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PT02706759T 2001-03-12 2002-03-12 ''factores neurotróficos'' PT1373503E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
PT1373503E true PT1373503E (pt) 2008-02-26

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02706759T PT1373503E (pt) 2001-03-12 2002-03-12 ''factores neurotróficos''
PT07120461T PT1930439E (pt) 2001-03-12 2002-03-12 Factores neurotróficos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT07120461T PT1930439E (pt) 2001-03-12 2002-03-12 Factores neurotróficos

Country Status (15)

Country Link
US (1) US20020055467A1 (https=)
EP (2) EP1373503B1 (https=)
JP (2) JP3738008B2 (https=)
CN (1) CN1268744C (https=)
AT (2) ATE509103T1 (https=)
AU (1) AU2002240943B2 (https=)
CA (1) CA2440767C (https=)
CY (1) CY1111750T1 (https=)
DE (1) DE60223511T2 (https=)
DK (2) DK1930439T3 (https=)
ES (2) ES2366610T3 (https=)
NZ (1) NZ528790A (https=)
PT (2) PT1373503E (https=)
SI (2) SI1930439T1 (https=)
WO (1) WO2002072826A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
HK1045528B (zh) * 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
NZ526610A (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the GDNF ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) * 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
EP1463530A4 (en) * 2001-12-19 2006-09-06 Lijun Wang ADENO-ASSOCIATED VIRUS-RELATED DELIVERY OF GDNF TO SKELETAL MUSCLES
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
WO2004094592A2 (en) * 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
WO2012041328A1 (en) * 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
KR20200144576A (ko) * 2018-05-17 2020-12-29 주식회사 헬릭스미스 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Lttバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
CN1163509C (zh) 1996-05-08 2004-08-25 拜奥根有限公司 刺激神经和肾生长的RET配体(RetL)
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor

Also Published As

Publication number Publication date
DE60223511D1 (de) 2007-12-27
EP1930439A1 (en) 2008-06-11
ES2366610T3 (es) 2011-10-21
CA2440767A1 (en) 2002-09-19
JP2005198656A (ja) 2005-07-28
PT1930439E (pt) 2011-07-25
JP2004531242A (ja) 2004-10-14
HK1120556A1 (en) 2009-04-03
DK1373503T3 (da) 2008-03-25
DK1930439T3 (da) 2011-08-29
CN1268744C (zh) 2006-08-09
WO2002072826A2 (en) 2002-09-19
EP1373503B1 (en) 2007-11-14
WO2002072826A3 (en) 2003-04-10
AU2002240943B2 (en) 2007-05-10
EP1373503A2 (en) 2004-01-02
EP1930439B1 (en) 2011-05-11
SI1930439T1 (sl) 2011-09-30
CA2440767C (en) 2012-05-29
NZ528790A (en) 2004-06-25
SI1373503T1 (sl) 2008-04-30
ATE378353T1 (de) 2007-11-15
ES2296899T3 (es) 2008-05-01
CN1509333A (zh) 2004-06-30
AU2002240943A2 (en) 2002-09-24
US20020055467A1 (en) 2002-05-09
DE60223511T2 (de) 2008-10-23
ATE509103T1 (de) 2011-05-15
CY1111750T1 (el) 2015-10-07
JP3738008B2 (ja) 2006-01-25

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
SI1095140T1 (sl) Nevrotrofični dejavniki
IL161016A (en) Polypeptides capable of ang-2 binding
PT1015585E (pt) Homologos de ligandos de tie
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2003080795A8 (en) Novel nucleic acids and secreted polypeptides
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2007045019A3 (en) Polyoleosins
WO2003025142A3 (en) Novel nucleic acids and secreted polypeptides
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
EA200100110A1 (ru) Нейротрофические факторы
WO2001057187A3 (en) Novel bone marrow nucleic acids and polypeptides
WO2001088091A3 (en) Novel bone marrow nucleic acids and polypeptides
TW200519206A (en) Methods for producing novel medaka and novel medaka
WO2002050274A3 (en) Seleno-cysteine containing protein zsel1
WO2004039319A3 (en) Novel human polypeptides encoded by polynucleotides